Johnson & Johnson (JNJ)vsKoninklijke Philips NV ADR (PHG)
JNJ
Johnson & Johnson
$265.58
-0.29%
HEALTHCARE · Cap: $640.02B
PHG
Koninklijke Philips NV ADR
$24.59
-0.04%
HEALTHCARE · Cap: $25.31B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 454% more annual revenue ($97.93B vs $17.66B). JNJ leads profitability with a 21.5% profit margin vs 6.3%. PHG appears more attractively valued with a PEG of 0.79. PHG earns a higher WallStSmart Score of 63/100 (C+).
JNJ
Buy59
out of 100
Grade: C
PHG
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-88.9%
Fair Value
$140.57
Current Price
$265.58
$125.01 premium
Margin of Safety
-55.6%
Fair Value
$20.61
Current Price
$24.59
$3.98 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Earnings expanding 61.4% YoY
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Expensive relative to growth rate
Earnings declined 0.9%
0.5% revenue growth
Distress zone — elevated risk
6.3% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bull Case : PHG
The strongest argument for PHG centers on EPS Growth, PEG Ratio, Price/Book. PEG of 0.79 suggests the stock is reasonably priced for its growth.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : PHG
The primary concerns for PHG are Revenue Growth, Altman Z-Score, Profit Margin.
Key Dynamics to Monitor
JNJ profiles as a mature stock while PHG is a value play — different risk/reward profiles.
PHG carries more volatility with a beta of 0.91 — expect wider price swings.
JNJ is growing revenue faster at 6.6% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
PHG scores higher overall (63/100 vs 59/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Koninklijke Philips NV ADR
HEALTHCARE · MEDICAL DEVICES · USA
Koninklijke Philips NV is a healthcare technology company in North America, Greater China and internationally. The company is headquartered in Amsterdam, the Netherlands.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?